DMPHF Stock - Dermapharm Holding SE
Unlock GoAI Insights for DMPHF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $1.18B | $1.15B | $1.02B | $942.91M | $793.83M |
| Gross Profit | $767.07M | $704.14M | $660.83M | $620.69M | $463.48M |
| Gross Margin | 65.0% | 61.2% | 64.5% | 65.8% | 58.4% |
| Operating Income | $216.93M | $182.89M | $243.69M | $298.47M | $136.85M |
| Net Income | $113.79M | $62.37M | $134.24M | $209.58M | $85.83M |
| Net Margin | 9.6% | 5.4% | 13.1% | 22.2% | 10.8% |
| EPS | $2.11 | $1.16 | $2.49 | $3.89 | $1.59 |
Dermapharm Holding SE, together with its subsidiaries, engages in the off-patent branded pharmaceuticals business in Germany and internationally. It operates through three segments: Branded Pharmaceuticals and Other Healthcare Products, Parallel Import Business, and Herbal Extracts. The company develops, manufactures, licenses, markets, and sells branded generics, over-the-counter drugs, non-prescription natural remedies, and other healthcare products. It also offers healthcare products in the areas of vitamins, minerals, food supplements, dermatology, allergology, pain and inflammation treatment, cardiovascular support, gynecology, and urology primarily under the Dekristol, Dekristolvit, Allergovit, and Tromcardin brands. In addition, the company provides medical devices under the bite away and Herpotherm names; Momekort, a nasal spray used to treat allergy symptoms; and Azedil, a nasal spray or eye drop. Further, it imports originator pharmaceuticals under the axicorp brand; and offers herbal extracts and natural active ingredients for phytopharmaceuticals, nutraceuticals, and cosmetics. It serves pharmaceutical wholesalers, pharmacies, hospitals, and health food stores. The company was founded in 1991 and is headquartered in Grünwald, Germany. Dermapharm Holding SE is a subsidiary of Themis Beteiligungs-Aktiengesellschaft.
Visit WebsiteEarnings History & Surprises
DMPHFEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 13, 2026 | — | — | — | — |
Q4 2025 | Nov 13, 2025 | — | $0.89 | — | — |
Q3 2025 | Aug 26, 2025 | — | $0.46 | — | — |
Q2 2025 | May 15, 2025 | — | $0.68 | — | — |
Q1 2025 | Mar 14, 2025 | — | $0.39 | — | — |
Q4 2024 | Nov 14, 2024 | — | $0.66 | — | — |
Q3 2024 | Aug 14, 2024 | — | $0.34 | — | — |
Q2 2024 | May 15, 2024 | — | $0.87 | — | — |
Q1 2024 | Mar 7, 2024 | — | $-0.05 | — | — |
Q3 2023 | Sep 30, 2023 | — | $0.49 | — | — |
Q2 2023 | Jun 30, 2023 | — | $-0.19 | — | — |
Q1 2023 | Mar 31, 2023 | — | $1.00 | — | — |
Q1 2023 | Mar 28, 2023 | — | $0.60 | — | — |
Q4 2022 | Nov 16, 2022 | $0.93 | $0.96 | +3.3% | ✓ BEAT |
Q3 2022 | Aug 31, 2022 | $0.76 | $0.27 | -64.2% | ✗ MISS |
Q2 2022 | May 18, 2022 | — | $0.69 | — | — |
Q2 2022 | Apr 12, 2022 | $1.51 | $1.51 | 0.0% | = MET |
Q4 2021 | Nov 16, 2021 | $0.98 | $1.15 | +17.3% | ✓ BEAT |
Q3 2021 | Sep 7, 2021 | — | $0.74 | — | — |
Q2 2021 | May 18, 2021 | $0.59 | $0.67 | +13.6% | ✓ BEAT |
Latest News
Frequently Asked Questions about DMPHF
What is DMPHF's current stock price?
What is the analyst price target for DMPHF?
What sector is Dermapharm Holding SE in?
What is DMPHF's market cap?
Does DMPHF pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to DMPHF for comparison